The double upgrade from Argus combined with strong institutional buying and rising EPS revisions creates a bullish convergence. Traders can use this as a catalyst entry point, with the $66.21 consensus mean as a near-term resistance level and $75 as a medium-term target.
BMY drugs
BMY drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 5 $63.63entry
- T+1 · 3mo ago +0.82%α +0.98% · $64.15
- T+5 · 3mo ago +0.11%α −0.24% · $63.70
- T+20 · 3mo ago +6.33%α +6.93% · $67.66
- T+60 · 19d ago −3.52%α −3.46% · $61.39
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Argus Research executes a double upgrade on BMY, moving from Hold to Buy with a $75 price target, implying 13.8% upside from the current $65.89. This is a positive contrarian call, only 24% of analysts rate BMY a Buy/Strong Buy and 48% Hold, while the consensus mean target of $66.21 is just 0.5% above current price. Argus holds a 54% accuracy rate across 339 calls with an average return of 3.7%, a solid track record for a double-upgrade signal. The 30-day analyst activity shows 1 upgrade and 0 downgrades, with earnings-per-share estimates for the current and next quarters revised upward over the past 7 and 30 days (6 up vs 5 down for current quarter, 12 up vs 1 down for next quarter). Institutional flows are strongly bullish, with major funds like Citigroup (+31.6%, $194M) and CIBC Asset Management (+57.4%, $44.7M) adding positions, and no insider sales or congressional trades to offset the signal. The short interest ratio of 58.5% on 3.9M shares short adds mild bearish pressure but does not outweigh the combined bullish analyst, institutional, and earnings revision momentum. The core message: a double upgrade from a mid-accuracy firm aligns with rising EPS estimates and large institutional buys, making this a meaningful bullish signal for BMY.
Impact Score
Consensus & Targets
Out of 35 analysts: 17% Strong Buy (6), 23% Buy (8), 54% Hold (19), 6% Sell (2), 0% Strong Sell. The consensus is heavily biased toward Hold, making Argus's double upgrade a contrarian call that breaks from the cautious majority.
Mean PT $66.21 (vs current $65.89, implied upside 0.5%), median $68, high $80, low $40. Argus's $75 target is 13.3% above the mean and 10.3% above the median, sitting in the top quartile of analyst targets.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-05 | Argus Research | upgrade | Buy | $75.00 |
| 2026-08-03 | Citigroup | maintain | Neutral | No target |
| 2026-07-31 | RBC Capital | maintain | Sector Perform | $64.00 |
| 2026-07-31 | JP Morgan | maintain | Overweight | $73.00 |
| 2026-07-31 | Cantor Fitzgerald | maintain | Neutral | No target |
| 2026-07-31 | Wells Fargo | maintain | Equal-Weight | No target |
| 2026-07-31 | Guggenheim | maintain | Buy | No target |
| 2026-07-31 | Truist Securities | reiterate | Buy | No target |
| 2026-07-10 | B of A Securities | maintain | Buy | $66.00 |
| 2026-07-06 | Cantor Fitzgerald | reiterate | Neutral | $54.00 |
30-day activity shows 1 upgrade (Argus) and 0 downgrades. EPS revisions: current quarter (+7d: 0 down, 1 up; +30d: 5 down vs 6 up) and next quarter (+7d: 3 up, 0 down; +30d: 1 down vs 12 up) show positive momentum. Current year (+30d: 6 down vs 12 up) and next year (+30d: 10 down vs 6 up) are mixed but short-term revisions are bullish.
Firm Track Record: Argus Research
Argus Research accuracy: 54% on 339 calls | avg return: 3.7%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 10 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Jefferies | 100% | 3/3 | 10.4% | top tier |
| Goldman Sachs | 100% | 2/2 | 10.3% | top tier |
| TD Cowen | 100% | 2/2 | 17.5% | top tier |
| BMO Capital | 80% | 4/5 | 10.2% | top tier |
| Cantor Fitzgerald | 80% | 4/5 | 6.7% | top tier |
| Morgan Stanley | 67% | 2/3 | 0.6% | top tier |
| UBS | 50% | 1/2 | 1.2% | below average |
| Citigroup | 40% | 2/5 | 6.4% | below average |
| Barclays | 40% | 2/5 | 16.9% | below average |
| Wells Fargo | 25% | 1/4 | -2% | below average |
Argus Research has a 54% accuracy rate (184 correct out of 339 scored) with an average return of 3.7%. Among 10 rated firms with available accuracy data, Jefferies (100% on 3 calls), Goldman Sachs (100% on 2), and TD Cowen (100% on 2) are top-tier but have minimal coverage. Wells Fargo is the lowest performer at 25% on 4 calls with a -2% average return. Argus sits in the middle cluster, making the double upgrade noteworthy but not elite-tier.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $1.73 | $1.59 to $1.92 | $12.7B | ↑1 ↓0 |
| +1q | $1.59 | $1.28 to $1.71 | $12.7B | ↑3 ↓0 |
| 0y | $6.95 | $6.80 to $7.15 | $49.8B | ↑3 ↓0 |
| +1y | $6.54 | $5.84 to $7.63 | $48.1B | ↑4 ↓0 |
Cross-Platform Signals
No insider trades or congressional activity reported. Institutional changes are strongly bullish: Citigroup added $194M (+31.6%), CIBC Asset Management added $44.7M (+57.4%), and Banco Santander added $62.7M (+34.7%). Walleye Capital doubled its position (23,084.6% change, $1.04M). Short interest is relatively high at 58.5% of TRF volume (3.9M shares), which could add squeeze potential if bullish momentum builds. The institutional buying and EPS revision uptrend converge with the analyst upgrade, no divergence signal.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
9 reports on BMY
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $62.14 to $62.14 Now $62.93 +1.27% · 0.00% −2.37% vs SPY
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $61.39 to $62.48 Now $62.93 +2.51% ▲ +1.78% +3.55% vs SPY
- Oct 23, 202624d ago Institutional Cluster Neutral 3/10 Entry $61.48 to $61.61 Now $62.93 +2.36% ▲ +0.21% −0.50% vs SPY
- Oct 5, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Aug 17, 202613w ago Institutional Cluster Bullish 6/10 Entry $64.63 to $66.05 Now $62.93 −2.63% ▲ +2.20% +2.87% vs SPY
- Aug 5, 202614w ago ANALYST-UPGRADE Bullish 4/10 Viewing Entry $63.63 to $64.15 Now $62.93 −1.10% ▲ +0.82% +0.98% vs SPY
- Jul 30, 202615w ago 8-K Bullish 7/10 Entry $64.86 to $65.31 Now $62.93 −2.98% ▲ +0.69% −0.01% vs SPY
- Mar 25, 202633w ago DEFA14A Neutral 3/10 Entry $59.39 to $58.47 Now $62.93 +5.97% ▼ −1.55% +0.13% vs SPY
- Feb 26, 202637w ago Court Ruling Neutral 3/10 Entry $62.37 to $62.34 Now $62.93 +0.90% ▼ −0.05% −0.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers